The Orphanet Nomenclature of rare diseases: a standard terminology for improved patient recognition and data interoperability

Caterina Lucano[1,*], David Lagorce[1], Annie Olry[1], Houda Ali[1], Valérie Lanneau[1], Mickael De Carvalho[1], Aysegul Dilsizoglu Senol[1], Marta Fructuoso[1], Emilie Gaillard[1,2], Marie-Cécile Gaillard[1], Seed Mihic[1], Mariana Tannoury[1], Florence Sauvage[1], Charlotte Rodwell[1], Sylvie Maiella[1], Marc Hanauer[1], Ana Rath[1,*]

[1]Inserm, US14-Orphanet, Paris, France

[2]French National Rare Disease Registry (BNDMR), Greater Paris University Hospitals (AP-HP), Paris, France

* Corresponding authors

E-mail: caterina.lucano@inserm.fr (CL)

E-mail: ana.rath@inserm.fr (AR)

Abstract

Although individually uncommon, rare diseases (RD) affect an estimated 300 million people worldwide. Establishing a public health approach to RD requires counting diseases and affected patients. However, RD are under-represented in medical terminologies, with only a small fraction of RD possessing specific and unambiguous codes, and those codes not being explicitly designated as rare.

To tackle the challenge of RD codification and interoperability, Orphanet has developed a nomenclature of RD that provides unique and time-stable disease identifiers (ORPHAcodes) and meets the gold standards for implementation in health information systems and systematic research collections. The Orphanet Nomenclature of RD is multilingual and versioned; its development and updates rely on standardized procedures, manual curation and expert validation, reflecting advancements in RD knowledge and clinical practice.

This work provides an overview of the Orphanet Nomenclature and classification system for RD, detailing its production, update and mapping methodology. As of July 2025, the Orphanet Nomenclature contains a total of 6,527 RD, multiclassified into 29 classifications, each corresponding to a medical domain, accurately representing the complex multisystemic nature of RD. Extensive qualified mappings ensure semantic interoperability across multiple terminologies. Overall, 97.4% of RD are mapped to at least one ICD-10 code (with only 6.3% exhibiting an exact equivalence), 71.7% are mapped to at least one ICD-11 code (15.3% with an exact equivalence) and 93.8% are mapped to SNOMED CT (all with an exact equivalence). Genetic diseases represent 72.2% of all RD, and 63.4% are mapped to at least one phenotypic OMIM number.

By addressing the underrepresentation of RD in medical terminologies, ORPHAcodes facilitate accurate patient identification, advance research and healthcare interoperability,

47   and help in shaping public health policies. The recognition of the Orphanet Nomenclature as

48   the most appropriate terminology for RD clinical coding in Europe underscores its critical role

49   in the global RD ecosystem.

Introduction

Cross-border data collection, sharing, and exploitation to support evidence-based policymaking, healthcare, and research are essential in the field of rare diseases (RD), as underscored by numerous international and European initiatives [1]. Although RD are individually uncommon, with over 6,000 different known RD, they collectively affect an estimated 300 million people worldwide [2]. The critical amount of data necessary to improve knowledge, care and treatment can thus only be achieved through cumulative data collection across different countries in a standardized manner [3,4].

The concept of RD first emerged in 1972 in Japan with the launch of the National Program on Rare and Intractable Diseases [5]. Since then, numerous definitions have been proposed, reflecting local legislations [4,6–11]. Most of these definitions use point prevalence as the common epidemiological indicator to define the rarity of a disease. However, the threshold for rarity varies geographically: less than one per 2,500 in Japan [5], less than 50 per 100,000 in Europe [12], or no more than 200,000 persons in the US, which translates to a prevalence of 86 per 100,000 at the time of the American Orphan Drug Act (1983) [13]. Furthermore, definitions can differ clinically, sometimes including restrictions such as "life-threatening" or "chronically debilitating" [6,12,14].

To address these definition inconsistencies, Rare Diseases International (RDI), in collaboration with a global panel of experts and the World Health Organization (WHO), has developed an Operational Description of Rare Diseases [15]. This work has defined a RD as a medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2,000 persons living in any World Health Organization-defined region of the world. The definition moreover emphasizes the need for a standardized approach to account for the unique challenges faced by individuals with RD, including long

diagnostic journeys, inadequate clinical management, and limited treatment options [15].

Despite this effort offering a path toward greater convergence, the continued lack of

harmonization among countries, combined with the limitations of the currently adopted

definitions, impacts research on RD mechanisms and therapies, diagnostic approaches, and

healthcare planning [1,3,8].

To take public health action on RD, the community needs to know how many people

are affected by these diseases (prevalence), how these conditions impact those affected, and

how to monitor their medical and societal consequences. Establishing a public health

approach to RD includes counting and measuring RD, which is essential to support actions that

reduce their impact on patients and society. This would improve health, quality of life, life

expectancy, disease management, and patient involvement in their communities and society

[2,4,16]. Indeed the United Nations Resolution on People Living with a Rare Disease

"encourages Member States and relevant United Nations agencies to collect, analyze, and

disseminate disaggregated data on persons living with a rare disease... to assess progress

towards the improvement of the status of persons living with a rare disease". This further

highlights that adequate coding of RD patient data is a prerequisite for an effective response

to this global public health priority [17].

However, RD are under-represented in medical terminologies used within health

systems, with only a small fraction of RD possessing specific and unambiguous codes [18–21].

This makes it difficult to trace patients with RD in health information systems at the national

level, preventing a robust understanding of the actual number of people affected by a RD.

Only a small proportion of RD have a specific code in ICD-10 [19–21]; the representation of RD

has increased in ICD-11 [20,22] and SNOMED CT [23], two other global medical terminology

standards, though it still remains below the number of known RD. Nevertheless, RD cannot be

easily identified in these generic systems, as they do not include any indication of the rarity of

a disease. Furthermore, different regions use diverse medical terminologies (e.g. the

International Classification of Diseases ICD or SNOMED CT) or diverse versions of the same

terminology (ICD local extensions, different ICD versions), hampering data sharing and

interoperability. Given the already scarce nature of RD data, this barrier to data collection

requires dedicated efforts to make RD recognizable in health information systems [24–26].

The availability of adequate codes for each RD is now a well-recognized need at

international level [24,26]. Improved codification for RD has been cited as a priority in the

2009 EU Council Recommendation on an action in the field of rare diseases [26], and more

recently by the Rare2030 recommendations [27]. Having codes for each RD would help

international, European, national, and local health authorities obtain better knowledge of

healthcare pathways and of their impact on both specialized (such as centers of expertise) and

general health care services as well as on budget planning for health and social services.

Improving the visibility of RD in healthcare information systems could help to define patient

pathways based on real-life data. A common standard for describing RD would also aid in

developing approaches to alleviate the substantial cumulative burden of RD [8,24,26].

Adequate coding is also necessary for identifying patients for clinical trials at both national

and transnational levels. Finally, a large proportion of RD patients remain undiagnosed despite

undergoing a full investigation, but this particular situation cannot be captured by the

codification systems in use.

To tackle the challenge of RD codification and interoperability, Orphanet has

developed and maintained a nomenclature of RD since 1997 and a classification of RD since

2006 [19,28]. In 2014, the Commission Expert Group on Rare Diseases adopted a

recommendation on improving RD codification [24]. In this document, Member States are

encouraged to assess the feasibility of implementing ORPHAcodes at a national level and to include RD codification into their national RD plans/strategies. In 2017, the EC Steering Group on Promotion and Prevention (SGPP) recognized ORPHAcodes as a best practice [29]. Since then, ORPHAcodes have been included in the set of common data elements for Rare Diseases Registration, released by the EU RD platform to enhance interoperability between registries [30]. The Orphanet Nomenclature of RD has also played a key role in implementing the EU 2011 Cross-Border Healthcare Directive as concerns RD. As a result, ORPHAcodes have been recommended for tracking RD diagnoses in the European Common Semantic Strategy (2019) [31] and the Guidelines on Patient Summary (Release 3.2, March 2022 and Release 3.4, November 2024) [32], and have been integrated into the Code Systems used in the MVC - My Health @ EU - eHealth Digital Service Infrastructure (eHDSI). The functional specifications developed by the X-eHealth project also include ORPHAcodes in the minimum dataset required for the electronic Patient Summary [32,33]. Finally, the WHO resolution "Rare diseases: a global health priority for equity and inclusion" adopted on the 24th of May 2025 urges Members States to commit to considering the implementation of ICD-11, and where appropriate, interoperable codification systems for RD such as the Orphanet Nomenclature of rare diseases, at their earliest possibility, and in accordance with their available resources, in order to enable the recording, reporting and monitoring of rare diseases at the national and international levels [34].

This paper presents an overview of the Orphanet Nomenclature and classification of RD, detailing its production and update methodology. It includes a clear and up-to-date count of RD based on the Orphanet knowledge base, as well as their distribution by medical domain, and information on mappings to other medical terminologies. Finally, this work highlights the

145   importance of maintaining a standardized and reliable RD nomenclature for clinical coding,

146   research, healthcare interoperability, and policy-making.

Materials and Methods

The structure of the Orphanet Nomenclature and classification of RD

The Orphanet Nomenclature of RD is composed of clinical entities, each of which includes several elements to ensure precise and unambiguous coding (Fig 1) [35]:

- ORPHAcode: a unique and time-stable numerical identifier automatically assigned in ascending order to every entry registered in the Orphanet Nomenclature;

- Preferred term (or main name): the most widely accepted name for the diagnosis in the literature and/or in the medical community;

- Synonym(s): additional terms perfectly equivalent to the preferred term, as many as necessary according to the information found in the literature;

- Classification level: indicates the level of precision of the clinical entity, among three possible granularity levels: Group of disorders, Disorder, or Subtype of disorder;

- Definition: a brief description of the major clinical characteristics that define the diagnosis and differentiate it from other clinically related clinical entities.

Fig 1. Technical elements composing the Orphanet Nomenclature of RD.

Example of a clinical entity in the Orphanet Nomenclature of RD, defined by an ORPHAcode, a preferred term, as many synonyms as needed, a classification level, and a textual definition.

In the absence of an international consensus on how to name diseases, preferred terms and synonyms are assigned according to standard naming rules developed by Orphanet

to create a comprehensive RD terminology that aligns with current knowledge and clinical

practice [36]. These rules ensure consistency across different disorder groups and medical

domains, facilitating better integration and use of RD-related clinical information in databases

and healthcare systems.

The Orphanet Nomenclature of RD is produced in English and entirely translated into

eight languages (French, German, Spanish, Italian, Dutch, Portuguese, Polish and Czech) by

translation teams located in member countries of the Orphanet Network. All translations are

validated by RD expert medical doctors in each country. The English terminology serves as

the basis for the translation of concepts; however, the translation process considers the

particularities and local practices specific to every language, in particular with regard to the

number of synonyms [37].

The Orphanet Nomenclature of RD is structured in a classification system composed

by the three classification levels above-mentioned, namely Group of disorders, Disorder, and

Subtype of disorder (Fig 2). The classification level serves as the basis for parent-child

relationships between related clinical entities. These relationships structure the classification

according to successive criteria that are relevant in the clinical setting [35]. Additionally, each

clinical entity is attributed a typology, a characteristic that, within the classification level,

conveys the nosological definition of the clinical entity. For Group of disorders, typologies

include Clinical group and Category; for Disorders, they include Disease, Clinical syndrome,

Biological anomaly, Malformation syndrome, Morphological anomaly, and Particular clinical

situation in a disease or syndrome; and for Subtype of disorder, they include Clinical subtype,

Etiological subtype, and Histopathological subtype (Fig 2) [35]. While generally used

interchangeably to accommodate the widespread use of the term "rare diseases", the terms

"disease" and "disorder" designate different concepts within the Orphanet Nomenclature of

RD. As previously explained, the term *disease* represents a narrower clinical concept, whereas

the term disorder is used to refer to the broader classification level [35].

Fig 2. Classification levels and typologies of the Orphanet Nomenclature of RD.

Every clinical entity in the Orphanet Nomenclature of RD is associated with a classification

level conveying the precision of the diagnosis (Group of disorder, Disorder, or Subtype of

disorder), and a unique typology within the classification level.

The Orphanet classification is also structured in 34 major classification groups,

individually referred to as classification hierarchy. Of these 34 classifications, 29 represent a

distinct medical domain, and 5 are ad-hoc classifications used for sorting purposes. These 5

hierarchies have been excluded from the analysis in this work, for the reasons outlined below:

-　Orphanet classification of rare genetic disorders: this classification does not represent

a distinct medical domain but is rather a derived genetic version that mirrors all the

other clinical classification hierarchies;

-　Orphanet classification of rare systemic or rheumatological disorders of childhood: this

classification is fully included into the Orphanet classification of rare systemic or

rheumatologic disorders;

-　Orphanet classification of rare transplant-related disorders: this classification does not

represent a medical domain but is used to class disorders according to a surgical

intervention;

-    Orphanet classification of teratologic disorders: this classification is fully included into

the Orphanet classification of rare developmental anomalies during embryogenesis;

-    Orphanet classification of rare disorder without a determined diagnosis: this

classification does not represent a medical domain and is used to class one single

disorder, ORPHA: 616874 Rare disorder without a determined diagnosis after full

investigation [38]. This is a code that allows the identification of undiagnosed rare

disorder patients in healthcare information systems and that does not conceptually

fall under any of the other Orphanet classification hierarchies.

Every classification consists in an arborescence structure that starts with a unique ultimate

parent group at the top representing the broadest clinical concept/the medical domain (head

of classification), then branching out into as many intermediate groups as necessary with

increasing precision of clinical concepts, until reaching the first level of the confirmed

diagnosis, the disorder. For any given disorder, subtypes can be added when this level of

precision is required in clinical practice for appropriate management and follow-up.

Every clinical entity in the Orphanet Nomenclature of RD is introduced in as many

classifications as necessary according to major medical specialties involved in the

management of the disorder. This results in a multi-hierarchical and multi-parental

classification structure that reflects the multi-dimensionality and complexity of RD (Fig 3).

However, only one ultimate parent group is chosen as the entity's preferential classification

for linearization (preferential parent), according to the most severely affected body system,

the most determining involvement for the prognosis, and/or the medical specialty that will

most likely be relied on for the management of the disorder [39]. This process, named

linearization, prevents concepts ambiguity in the presence of multiple classifications and

enables coherent statistical analysis.

Fig 3. Representation of a disorder in the Orphanet classification system.

The disorder Atypical Hemolytic Syndrome (ORPHA:2134) is listed under four classifications. It has two direct parent groups, each with broader parent groups, culminating at the top of the hierarchy, where each ultimate parent group represents a medical domain. The Rare Renal Disorder group (ORPHA:93626) was designated as the preferential parent of the disorder Atypical Hemolytic Syndrome (ORPHA:2134). Note that all groups in the figure have additional child entities not shown here.

Production and update process of the Orphanet Nomenclature of RD

The Orphanet Nomenclature of RD is produced and updated according to a standardized and published procedure, in order to maintain a maximum level of quality of the information, by a scientific team of information scientists at the Institut national de la santé et de la recherche médicale (Inserm) US14 service unit, Paris, France. The information provided in the Orphanet Nomenclature is sourced from up-to-date scientific and medical literature (more than 2,000 papers are consulted yearly), manually curated, reviewed and validated by Orphanet information scientists and RD medical experts, when pertinent [35,40].

The maintenance of the Orphanet Nomenclature of RD is ensured through three main types of actions:

- the **inclusion** of a new clinical entity: to be included in the Orphanet Nomenclature, a clinical entity must represent a clinically homogeneous phenotype with a prevalence of no more than five in 10,000 people and be described in at least two individuals in

265   the literature [15]. Before inclusion, the clinical entity is compared with existing

266   entities to avoid overlaps and ensure classification consistency;

267   -   the **modification** of an existing entity: a clinical entity in the Orphanet Nomenclature

268   of RD can be modified to improve or update its information, including the preferred

269   term, synonyms, classification level, typology or the definition. Clinical entities

270   described before the genetic era, and lacking publications since then, are labeled as

271   "Historic" and are kept in the Orphanet Nomenclature because their initial descriptions

272   are still available and carry a potential for further characterization;

273   -   the **inactivation** of a clinical entity: a clinical entity in Orphanet can be inactivated due

274   to deprecation (it is now included in another concept), obsolescence (it has no valid

275   reason to exist, such as being an imprecise or duplicate concept), or for not meeting

276   the rare disorder prevalence criteria anymore.

To ensure continuity of information, especially in health information records and coding

systems, Orphanet provides a replacement active clinical entity for deprecated and obsolete

entities. This replacement code, or target code, must be used instead of the corresponding

deprecated clinical entity as it aligns with the evolution of knowledge in the literature. For

obsolete entities, the target often refers to a group of disorders, guiding users to explore the

relevant classification to identify the most appropriate replacement code based on the

patient's diagnosis. Entities inactivated as non-rare in Europe are not given a replacement

code, as they no longer fall under the RD scope.

An ORPHAcode is permanently linked to the same clinical concept and is never deleted

nor reused for a different entity, even if the original entity becomes inactive. In rare instances,

an inactive clinical entity may be reactivated after reexamination with updated knowledge

and reintroduced into the Orphanet Nomenclature and classification with all relevant

scientific information.

Mappings to other reference terminologies

The Orphanet Nomenclature of RD is mapped to international terminologies and

reference databases according to a standardized and published procedure, to enable

interoperability between different information systems [41]. Target terminologies include

ICD-10 [42], ICD-11 (MMS and Foundation) [43], SNOMED CT [44,45], OMIM [46], UMLS [47],

MeSH [48], MedDRA [49], GARD [50], and MONDO [51].

The mapping cardinality always goes from the ORPHAcode to a code of the target medical

terminology. All mappings are qualified by a proximity relationship that defines the nature of

the correspondence between the two concepts. The adopted proximity relationships are:

- E (Exact): the Orphanet entity designated by an ORPHAcode and the target code have

the same range of application, they describe the same pathological entity;

- BTNT (Broader Term to Narrow Term): the Orphanet entity designated by an

ORPHAcode has a broader range than the target code;

- NTBT (Narrow Term to Broader Term): the Orphanet entity designated by an

ORPHAcode has a narrower range than the target code.

Moreover, the mappings with the WHO International Classification of Diseases (ICD-10 and

ICD-11) [41] are further characterized by a specificity relationship, namely:

- Specific code: the ORPHAcode has its own code in the ICD-10/ICD-11 Mortality and

Morbidity Statistics (MMS);

-   Index term: the Orphanet entity is listed in the ICD-10 alphabetical index/in the ICD-11

Foundation;

-   Inclusion term (ICD-10 only): the Orphanet entity is included under an ICD-10 category

in the tabulated list under the code but it has not its own code;

-   Attributed code: the ICD-10/ ICD-11 MMS code is attributed by Orphanet because of

the lack of matching terms.

All mappings are manually curated and validated by a medical doctor before publication,

unless explicitly marked as *Not yet validated* to indicate pending medical review.

Data extraction and analysis

Data metrics from the Orphanet Nomenclature of RD were computed using the

Orphanet Scientific Knowledge Files delivered on the Orphadata Science website [52]. These

datasets, structured in an Extensible Markup Language (XML) file format, are derived from the

Orphanet Knowledge base, which is also accessible through the Orphanet website [28]. They

are delivered twice a year in July and December and all previous versions are archived in a

dedicated GitHub repository [53]. For this study, we analyzed 4 datasets of the 2025 release:

-   the rare diseases and alignments with terminologies and databases dataset

(<iso>_product1.xml) in English, Czech, Dutch, French, German, Italian, Polish,

Portuguese and Spanish languages; version 1.3.42 / 4.1.8 [2025-03-03] released 24 Jun

2025, available at https://sciences.orphadata.com/alignments/

-   the linearization of rare diseases English dataset (en_product7.xml); version 1.3.42 /

4.1.8   [2025-03-03]   released   24   Jun   2025,   available   at

https://sciences.orphadata.com/linearisation/

- the genes associated with rare diseases English product (en_product6.xml); version

1.3.42 / 4.1.8 [2025-03-03] released 24 Jun 2025, available at

https://sciences.orphadata.com/genes/

- The classifications of rare diseases English datasets (en_product3_<x>.xml); version

1.3.42 / 4.1.8 [2025-03-03] released 24 Jun 2025, available at

https://sciences.orphadata.com/classifications/

Metrics were computed by using Python 3.8 scripts freely available in dedicated Jupyter

Notebooks (.ipynb files) shared in a Binder/Github-ready repository

(https://github.com/Orphanet/orphanet_nomenclature_binder). This repository provides a

publicly accessible, reproducible, and interactive computational environment that enables on-

demand calculation of metrics using Orphadata files. Eight scripts have been coded in order

to calculate the necessary metrics:

- 1_number_of_Orphanet_clinical_entities

- 2_production_of_the_Orphanet_RD_terminology_in_english_and_other_languages

- 3_proportion_of_genetic_versus_non_genetic_Orphanet_RD

- 4_number_of_Orphanet_RD_monoclassified_vs_multiclassified

- 5_distribution_of_Orphanet_RD_in_Orphanet_classifications

- 6_distribution_of_Orphanet_RD_by_preferential_parent

- 7_alignment_between_Orphanet_RD_and_international_terminologies

- 8_number_of_Orphanet_RD_with_definition_in_all_languages

Each script in the Jupiter Notebook has been annotated to clarify the calculation methodology.

The human readable Orphanet-SNOMED-CT mapping file (ORPHA-

SNOMEDCT_Mapping_File_production.xlsx); July 2024 version, released 15 Oct 2024,

available at: https://www.orphacode.org/pack-nomenclature/ was also used to report on the

Orphanet-SNOMED CT mappings.

Results

The Orphanet Nomenclature of RD

As of July 2025, the Orphanet Nomenclature of RD contains a total of 9,784 active clinical entities, including 6,527 disorders (among which is a specific disorder code for undiagnosed patients after full investigation [38]), 1,084 subtypes of disorders, and 2,173 groups of disorders. Among all active entities, 3.3% (325 disorders and 1 subtype) are considered historic, with no publications over the last 25 years. The distribution of all active clinical entities by their classification level and their typology is presented in Table 1 and in S1 File.

Table 1. Distribution of active clinical entities in the Orphanet Nomenclature of RD by classification level and typology.

	Number of active clinical entities	% on total clinical entities	% on each classification level
Disorders	**6,527**	66.7%	
Diseases	4,172		63.9%
Clinical syndromes	50		0.8%
Malformation syndromes	1,788		27.4%
Morphological anomalies	446		6.8%
Biological anomalies	11		0.2%
Particular clinical situations in a disease or syndrome	60		0.9%

Subtypes of disorders	**1,084**	11.1%	
Clinical subtypes	839		77.4%
Etiological subtypes	195		18.0%
Histopathological subtypes	50		4.6%
Groups of disorders	**2,173**	22.2%	
Clinical groups	450		20.7%
Categories	1,723		79.3%

Columns indicate the number of active clinical entities for each classification level and

typology, their percentage relative to the total number of clinical entities (n=9,784), and the

percentage each typology represents within its respective classification level.

Since Orphanet started tracking inactivations in 2013, 1,455 clinical entities have been

inactivated and therefore excluded from the Orphanet Nomenclature of RD. Of these, 378

were groups of disorders, 809 were disorders and 268 were subtypes of disorders. The reason

for inactivation is obsolescence for 68% of the cases (988 entities), deprecation for 22% (323

entities) and the fact that the disorder has been recognized as non-rare for the remaining 10%

(144 entities).

Since 2020, an average of 123 ± 72 (mean ± SD) new disorders per year have been

added to the Orphanet Nomenclature, while an average of 44 ± 18 disorders per year have

been inactivated. A detailed report of the number of newly included, obsoleted, deprecated

and non-rare disorders for each year from 2020 to 2025 is provided in Table 2.

Table 2. Yearly overview of the newly included and inactivated disorders in the Orphanet Nomenclature of RD (2020-2025).

	Newly included disorders	Obsoleted disorders	Deprecated disorders	Non rare disorders
2020	74	35	24	5
2021	53	8	16	1
2022	92	29	5	4
2023	114	21	8	5
2024	253	38	22	9
2025	152	13	19	2

Number of disorders newly included, obsoleted, deprecated, or identified as non-rare in the Orphanet Nomenclature of (RD), based on annual July dataset releases from 2020 to 2025.

Of the 9,784 active clinical entities in the Orphanet Nomenclature of RD, 6,311 (64.5%) carry at least one synonym in English, while the remaining 3,473 (35.5%) are not associated with any synonym. Of the 6,527 disorders, 4,805 (73.6%) carry at least one synonym in English, with a total number of synonyms at the disorder level amounting to 10,547. The minimum number of synonyms associated to a disorder is 1, and the maximum is 15, with a mean number of 2.2 synonyms for disorders with at least one synonym. The complete distribution of synonyms by classification level is reported in S2 File.

All preferred terms associated with active clinical entities registered in Orphanet Nomenclature of RD are translated in the following languages: French, German, Spanish, Italian, Dutch, Portuguese, Polish and Czech. Table 3 shows the rate of translation of preferred

terms for every language. The very minor delay in translation is due to the different timings

and frequencies at which translations are processed by every translation team. Non translated

preferred terms are nevertheless included in English, pending translation. Synonyms can be

adapted in all translated languages according to the medical practice in the target language;

the number of adapted synonyms for every translation language is shown in Table 3. The

complete distribution of synonyms by classification level in all translated languages is reported

in S2 File.

Table 3. Number of active entities with translated preferred term and adapted synonyms

per the target language.

	FR	DE	ES	IT	NL	PT	PL	CS
Number of translated preferred terms	9,784	9,778	9,784	9,569	9,777	9,576	9,605	9,628
% of translated preferred terms	100%	99.9%	100%	97.8%	99.9%	97.9%	98.2%	98.4%
Number of adapted synonyms	13,000	12,854	12,912	11,234	14,546	5,858	12,804	14,298

Number and percentage (%) of active clinical entities with a translated preferred term

available per language, relative to the total number of entities with English preferred terms

(n=9,784). The table also shows the number of adapted synonyms per language. Data for

French (FR), German (DE), Spanish (ES), Italian (IT), Dutch (NL), Portuguese (PT), Polish (PL),

and Czech (CS) were manually reviewed to identify untranslated terms.

Additional translations are also available in Chinese (9,158 translated preferred terms,

last update June 2020), Turkish (9,168 translated preferred terms, last update September

2021) and Ukrainian (9,612 translated preferred terms, last update July 2024), and are

provided in separate files in the "Rare Diseases and Alignment with Terminologies and

Databases" section of Orphadata Science [52].

Disorder definitions are produced in English for all disorders included in the Orphanet

Nomenclature of RD and are subsequently translated into the eight translation languages:

French, German, Spanish, Italian, Dutch, Portuguese, Polish and Czech. Table 4 presents the

coverage of disorder definitions at the disorder level in each language. Currently,

approximately 94% of rare disorders have a definition in English, while the rate of coverage in

other languages depends on the priorities defined by each translating country.

Table 4. Number of disorders with an available definitions per language.

	EN	FR	DE	ES	IT	NL	PT	PL	CS
Number of disorders with a definition	6,116	5,941	4,572	6,095	4,592	6,068	1,186	1,372	17
% on the total number disorders	93.7%	91.0%	70.1%	93.4%	70.4%	92.9%	18.2%	21.0%	0.26%

438   Number and percentage (%) of disorders with an available definitions in English (EN) and

439   translations into French (FR), German (DE), Spanish (ES), Italian (IT), Dutch (NL), Portuguese

440   (PT), Polish (PL), and Czech (CS). Percentages are calculated based on the total number of

441   disorders (n=6,527) in the Orphanet Nomenclature of RD.

The Orphanet classification of RD

The Orphanet classification of RD has a multi-parental structure: 4,415 (67.7%) disorders are classed in more than one classification hierarchy while 2,106 (32.3%) are classed in just one classification, independently of the number of parents that they have in this same hierarchy. Of the 34 classification hierarchies in the Orphanet classification system, 29 were included in the analysis. Five hierarchies not corresponding to distinct medical domains or representing organizational or non-clinical groupings, were excluded as previously described in the Methods section.

The majority of rare disorders are linearized into the rare developmental defect during embryogenesis classification (32.3%, 2,109 disorders), closely followed by the rare neurologic disorders classification (16.8%, 1,096 disorders), amounting together to almost 50% of all rare disorders. The following most represented classifications are the rare neoplastic disorders at 7.6%, the rare inborn errors of metabolism at 6.1%, the rare skin disorders at 6%, the rare bone disorders at 5.4%, the rare ophthalmic disorders at 3.7%, the rare immune disorders at 3.2%, the rare endocrine disorders at 3%, the rare hematologic disorders at 2.8%, the rare infectious disorders at 2.7%, and the rare systemic or rheumatologic diseases at 2.5%. The remaining classifications each include fewer than 100 linearized disorders each, collectively representing the residual 8% of rare disorders (Figure 4 gray bars, detailed in S3 File).

Fig 4. Distribution of rare disorders by medical domain according to their classification. Grey bars represent the number of disorders linearized according to their preferential parent classification, while white bars indicate the distribution of multi-classified disorders, counted as many times as they appear in the relevant classification hierarchies. Classifications

containing fewer than 100 disorders each are annotated with exact counts to enhance

readability. Six disorders were excluded from this analysis as they were either biological

anomalies without clinical manifestations or were linearized under the classifications of rare

genetic disorders or rare transplant-related disorders. ORPHA:616874 Rare disorder without

a determined diagnosis after full investigation was also excluded.

The majority of multiclassified rare disorders are again found in the rare

developmental defect during embryogenesis classification (2,793 disorders) and the rare

neurologic disorders classification (2,492 disorders). The following classifications contain

considerably less multiclassified disorders and are, in descending order: rare ophthalmic

disorders (868 disorders), rare skin disorders (835 disorders), rare bone disorders (793

disorders), rare neoplastic disorders (743 disorders), and rare inborn errors of metabolism

(704 disorders). The remaining hierarchies each contain less than 500 disorders, with only 3

hierarchies containing less than 100 (Figure 4 white bars, detailed in S3 File).

Description of the mappings between the Orphanet Nomenclature of RD and other

reference terminologies

Of the 6,527 active disorders registered in Orphanet, 6,355 (97.4%) are aligned to at

least one code ICD-10, with only 415 (6.4%) having an exact proximity relationship. The

remaining aligned codes are either present in the ICD-10 alphabetical index/are included in

the tabulated list under the ICD-10 code (655 disorders) or they have been attributed by

Orphanet to the ICD-10 code that corresponds to the closest entity according to Orphanet's

rules. The work on ICD-11 mapping has not been completed yet, however, as of July 2025,

4,683 disorders (71.8%) were aligned to at least one code in the ICD-11 MMS, with 958 (14.7%)

characterized by an exact proximity relationship and 3,013 (46.2%) present in the alphabetical

index/present in the ICD11 Foundation with an exact uri. The remaining mappings have been

attributed by Orphanet to the ICD-11 code corresponding to the closest entity. According to

the October 2024 release of the Orphanet-SNOMED CT mapping [54], 6,124 active disorders

(93.8%) are mapped to one SNOMED CT code, all with an exact proximity relationship (Table

5). Among all active disorders present in the Orphanet Nomenclature, 72.2% (n= 4,715) are

genetic disorders. A total of 4,141 disorders are mapped to at least one phenotypic OMIM

number and 3,319 mapped disorders have an exact proximity relationship (Table 5).

Table 5. Number of active disorders mapped to reference terminologies

A.	Number of active disorders with at least one mapping	% on total	Number of active disorders with an exact proximity relationship	% on total
ICD-10	6,355*	97.4%	415	6.4%
ICD-11	4,683*	71.8%	958	14.7%
SNOMED CT	6,124	93.8%	6,124	93.8%
B.	Number of active genetic disorders with at least one mapping	% on total	Number of active genetic disorders with an exact proximity relationship	% on total
OMIM	4,141	63.4%	3,319	50.9%

A) Number and percentage (%) of Orphanet active disorders mapped to ICD-10, ICD-11, and

SNOMED CT medical terminologies. Asterisks (*) indicate the inclusion in the total of mappings

attributed by Orphanet when the rare disorder was not present in the target terminology; B)

Number and percentage (%) of Orphanet active genetic disorders mapped to OMIM (Online

Mendelian Inheritance in Man). Percentages reflect the proportion relative to the total

number of disorders (n=6,527).

Discussion

While collectively common, RD are numerous, clinically heterogeneous, and share challenges directly related to their individual rarity: persons living with each RD are few and dispersed, knowledge about each RD is limited and often inaccessible to non-specialist health professionals, and expertise is scarce and dispersed as well. RD are hard to identify in medical records since most are absent from medical terminologies in use in hospitals or not labeled as rare, rendering them invisible in health systems. This lack of identification results in inequalities in accessing a timely diagnosis and appropriate care, hinders data collection on RD natural history and their personal and societal burden, and complicates patient recruitment for clinical research and therapy development [4,8,16,55].

RD codification requires a nomenclature that meets the standards of a medical terminology to ensure implementation in health information systems and in systematic research collections, such as patient registries. Simply maintaining an inventory of RD is not sufficient to address the codification challenge. A trustworthy and reliable medical terminology must meet strict quality requirements: univocity and unambiguity of coded concepts, unrestricted management of synonyms, consistency of semantic relationships between concepts, multilingual support, accuracy of translations, correctness of semantic alignments, and relevant coverage of identified use cases. Additionally, terminology standards must adhere to rigorous and essential quality procedures, ensure sustainability and scalability to support the rapid development of knowledge, and guarantee long-term stability, preservation of the meaning of concepts from previous versions, and traceability of changes [56]. Since 1997, Orphanet has maintained through its publicly available website an inventory of RD to provide information on RD and their dedicated services across Europe [28]. To

address the gaps in the classification and codification of RD identified in the 2009 Council

Recommendation, the European Commission supported Orphanet, though a number of EU

funded projects, in developing a nomenclature of RD, which has evolved over time into the

only RD-specific standardized codification and classification system meeting the high-quality

standards of a medical terminology [19].

To meet the univocity and unambiguity criteria, Orphanet adopted a clinical definition

of RD that encompasses all RD, regardless of whether the etiology is known or not. This core

concept ensures a terminology that can be adapted to different use cases, i.e. health systems

with diverse diagnostic capabilities or different stages of the patient's diagnostic journey. A

RD in Orphanet is therefore defined as a clinical entity characterized by a set of homogeneous

phenotypic abnormalities, described in at least two independent cases in the medical

literature, and a consistent evolution, allowing for a definitive clinical diagnosis. The rarity of

a disease is defined according to the European prevalence threshold (not more than 1 in 2,000

persons in the European population). This choice was made for historical reasons, as Orphanet

was developed in Europe and co-funded by the European Commission, in particular for the

development of the Orphanet Nomenclature of RD. However, this definition is consistent with

those used in other geographical areas, which adopt a similar or a more restrictive cutoff, with

the exception of the United States, which includes diseases with a higher prevalence [2].

Another limitation of this definition is that it includes rare infectious diseases in Europe, even

if they are common in other parts of the world. To address this, some countries having

adopted the Orphanet Nomenclature of RD outside the European space, like Argentina, have

adapted this chapter to exclude infectious diseases that are common in their countries [57].

These limitations underline the need for consensus around a global operational definition of

RD, a goal the WHO has worked towards in collaboration with RDI, with the participation of a

multi-stakeholder, international group of experts including an Orphanet representative (A.R.)

[15]. The results of this work support Orphanet's adoption of a clinical definition of RD and

may lead in the future to an adaptation of the Orphanet RD lists to the different WHO regions.

In the meantime, Orphanet collaborates with non-European countries to help adapt the

Orphanet Nomenclature of RD to local needs, improving global RD interoperability.

A consensus on the definition of RD also allows to unambiguously count the number

of existing RD. Many enumerations of RD circulate, some derived from semi-automated

integrations of different databases and ontologies (most frequently Orphanet and OMIM),

sometimes resulting in estimates exceeding 10,000 RD [8,58,59]. However, these methods

aggregate different levels of granularity without clearly stating which RD definition is adopted.

While this overall figure aligns closely with Orphanet's total active clinical entities (9,784 as of

July 2025), it is essential to recognize that superimposing different levels of granularity and/or

different etiologies of the same RD can lead to overcounting the same disease multiple times.

Indeed, from a methodological point of view, it is necessary to define the object to be

enumerated in order to achieve a reliable result. In this respect, the Orphanet Nomenclature

of RD and its classification system are unique in distinguishing between groups, disorders (RD

as defined by the criteria above), and subtypes within its 9,784 active clinical entities. This

allows for a precise count of RD (i.e. disorder classification level), which, as of July 2025 totals

6,527. More than the numbers themselves, it is their interpretation and impact that matter.

For epidemiological and public health purposes, the count of clinically defined RD provides an

appropriate indicator for comparing countries and healthcare systems with varying

technological and diagnostic capacities. Conversely, for precision medicine or molecular

diagnosis, a more granular approach including subtypes or genetic variants may be needed.

Estimates exceeding 10,000 RD often reflect the growing knowledge of disease mechanisms

and treatable variants rather than an actual increase in the number of RD. However, using this

broader count in public health discussions without clarification can lead to misinterpretations,

potentially affecting policy decisions, budget allocation, and healthcare planning.

The field of RD is a rapidly evolving one: with the continuous advancement in genetic

knowledge and the growing interest in personalized medicine, new RD are described each

month. Additionally, the perimeter of previously identified RD can be refined, with medical

concepts being either merged or divided based on new discoveries or the examination of

larger numbers of patients. To ensure that the Orphanet Nomenclature and classification of

RD remains up to date with current scientific knowledge, Orphanet conducts a monthly

systematic review of the literature and continuously collaborates with medical experts,

particularly from European Reference Networks (ERNs) and international RD learned societies

[40,60]. All modifications to ORPHAcodes are performed after an extensive review of the

literature and are validated by the Orphanet medical and scientific committee, following

published standardized procedures [35]. Between 2020 and 2025, a total of 738 new RD were

included in the Orphanet Nomenclature of RD, averaging about 120 diseases per year. This

number reflects not only newly described RD, but also the outcomes of numerous

time-effective collaborative projects with experts, aimed at restructuring and updating the

classification to incorporate revised medical concepts. At the same time, Orphanet also

applies a strict inactivation policy to preserve the stability and univocity of ORPHAcodes.

Inactivated codes are never reused for different entities, and a substitution code is always

suggested to maintain traceability. While unusual, it is possible to reintroduce an inactivated

ORPHAcode when new evidence emerges that justifies a reconsideration [35]. This has

occurred in cases such as Systemic lupus erythematosus ORPHA:536 and Immunoglobulin A

nephropathy ORPHA:34145, which did not initially meet Orphanet's criteria for being

considered RD. Taken together, the integration of new RD and the number of inactivated ones

contribute to a small and relatively stable annual increase in the total number of RD, averaging

fewer than 80 diseases per year.

To further ensure the univocity and accessibility of concepts, Orphanet implements an

unrestricted management of synonyms, aiming to maximize semantic coverage across

different usages and data sources. Among the 6,527 active RD, 73.6% have at least one

synonym in English, totaling 10,547 terms. Synonyms must cover the exact concept perimeter

and are added as needed, without limitations in number [35]. The number of synonyms per

RD ranges from 1 to 15, with a mean of 2.2 for RD carrying at least one synonym. Additionally,

Orphanet provides a standardized, medically validated definition for each RD included in the

Orphanet Nomenclature. These definitions consist of short texts describing the clinical

features to unambiguously delineate the entity and distinguish it from other RD, and are

intended to support healthcare professionals in assigning the correct ORPHAcode to a patient

[35,61]. To further ensure international interoperability, the Orphanet Nomenclature and

classification of RD is also a multilingual resource. Translations are performed according to

established procedures that include a final manual medical validation [37]. The different

translations also include an unlimited number of synonyms, that are tailored according to the

relevance to each language. Taken together, these elements ensure semantic consistency and

facilitate ORPHAcode integration into health and research information systems, optimizing

their use for medical practitioners and coders across countries and contexts and facilitating

cross-border data comparison and sharing.

To ensure that the Orphanet Nomenclature of RD could effectively be used across

various use cases and settings, RD are embedded in a three-level classification system:

disorders, group of disorders and subtype of disorders. While the disorder level serves as the

primary reference level for data sharing among systems and countries, and for

epidemiological purposes, groups of disorders allow data aggregation for use cases analysis,

i.e. for public health and decision-making purposes, and subtypes of disorders allow to fine-

tune RD codification, at the clinical, etiological and histopathological level. This classification

structure in which each level and their respective relationships are clearly defined, responds

to the criterion of consistency of semantic relationships between concepts. This system is able

to respond to the needs of different stakeholders and use cases: RD groups can be used for

public health analysis, the disorder level serves as the aggregation level for RD counting and

epidemiological studies, and the more granular subtypes can be used for applications in

genetics, precision medicine, and other research and innovation purposes [62–68].

Furthermore, the Orphanet Nomenclature of RD is the only one providing a code for

undiagnosed RD patients who underwent all available diagnostic possibilities: this RD

population has been estimated to up to 50% of all RD patients, based on the experience of RD

expert centers [38]. Being able to code these patients makes it possible to bring them to a

research pathway and undiagnosed programmes, as recommended by IRDiRC's goal #1 [69–

71]. Moreover, this classification system can capture the multisystemic nature of RD, as

clinical entities are organized into 29 distinct medical domains and classed as many times as

needed according to their relevant domain of care. This is reflected in the distribution of RD

across classification hierarchies: the majority of RD fall within the rare developmental defect

during embryogenesis and rare neurologic disease classifications, together accounting for

nearly 50% of all RD. However, almost 70% of RD are classed in more than one classification,

reflecting their multisystem involvement. This approach ensures a more accurate

representation of the complex nature of RD and of their linked resources, allowing to better

orient patients and medical doctors towards appropriate information and specialized care

[62–64].

RD is a field in which the boundaries between diagnosis, healthcare, and research are

often blurred, therefore maintaining semantic interoperability between health and research

sectors is essential. Semantic interoperability is the ability of different systems to exchange

information so that each of them can interpret the meaning of the information correctly,

without altering it, and use it in conjunction with its own local data. Achieving this requires

the use of standardized and interoperable information, as well as the coding of data using

semantic resources, such as reference terminologies, value sets, and semantic alignments.

Semantic interoperability with other reference terminologies used in healthcare (ICD-10, ICD-

11, SNOMED CT), research (OMIM and others), or regulatory settings (MedDRA) is maintained

according to specific rules that comprise cardinality and conceptual equivalence information.

This allows for interoperability between settings using terminologies that are based on

different concept definitions (for instance OMIM, in which concepts are defined genetically

[46], or MeSH, in which concepts aggregate related terms useful to improve medical literature

research, or ICD-10, in which different disease concepts can relate to a same broad concept

code). As of July 2025, Orphanet has aligned 97.4% of its active RD to at least one ICD-10 code,

with 6.4% exhibiting an exact proximity relationship. The work on ICD-11 mapping is ongoing,

but by July 2025, 71.8% of Orphanet's RD were mapped to at least one ICD-11 MMS code,

with 14.7% showing an exact proximity relationship. Additionally, the October 2024 release of

the Orphanet-SNOMED CT mapping shows that 93.8% of Orphanet's active RD are mapped to

SNOMED CT, with all exhibiting an exact proximity relationship. Regarding genetic diseases,

Orphanet classifies 72.2% of its active RD as genetic (defined as either caused by a known gene

or having a clear familial inheritance pattern) with 4,141 RD mapped to at least one

phenotypic OMIM number. It is interesting to note that many genetic RD are mapped to

multiple OMIM numbers, reflecting the fact that Orphanet defines diseases as clinical entities,

whereas OMIM organizes entries around individual gene-phenotype relationships. Overall,

this extensive and accurate mapping system ensures consistency of transcoding across

multiple platforms, further enhancing the utility of the Orphanet Nomenclature of RD in

clinical, research, and regulatory contexts [65–68,72,73]. It is important to note that Orphanet

is currently the only producer of a scientifically validated nomenclature of RD. Other

terminologies are increasingly integrating Orphanet concepts as a source of RD information,

acknowledging the critical scientific contributions Orphanet has made to the RD community.

Outstanding collaborations between Orphanet, SNOMED International and WHO ensure that

the RD content of SNOMED CT and the ICD-11 continues to be improved by the inclusion of

RD concepts defined by Orphanet [22,23].

To support the effective and sustainable implementation in health and research

information systems, the Orphanet Nomenclature of RD (ORPHAcodes) is distributed under

an open license (CC-BY 4.0) on different platforms depending on use: Orphadata Science for

structured datasets intended for large-scale analyses [52], and Orphacodes platform for

coding resources [54]. Each release is versioned and accompanied by differential files to

ensure traceability of changes and continuity of coding, as per recommendation of the RD-

ACTION working group for routine maintenance of codification [74]. In addition, a suite of

technical tools is provided to facilitate implementation into diverse systems, promote

accurate patient codification, and ensure continuous support by the community. This

supporting infrastructure ecosystem, on top of the production and dissemination of the

Orphanet Nomenclature of RD, is essential to ensure evolutivity and respond to emerging use

cases in a rapidly evolving field.

Conclusion

Improved codification of RD has been recognized as a strategic priority within the European policy landscape and has been the subject of a series of official recommendations. Accurate codification is the foundation for accurately producing, collecting and sharing high-quality data essential to increase the knowledge in a field that has long remained largely invisible within health systems. Establishing a seamless data ecosystem for RD based on the Orphanet Nomenclature and classification of RD has been recommended as a key step toward improving the lives of people living with a rare disease [27]. Indeed, accurate codification of RD patients allows to produce data both for primary and secondary use. Primary use includes: recognition of the RD condition by non-expert health professionals, raising awareness on RD specificities ensuring best care practices at all stages of the patient's care pathway, and recognition of undiagnosed RD patients who might benefit from new discoveries, potentially leading to establishing a diagnosis. Secondary use of RD data includes: accurately measuring the prevalence of the entire RD population and monitoring public health interventions to inform evidence-based decision-making, production of real-world evidence for research and therapeutic development, and facilitating recruitment for clinical research.

The Orphanet Nomenclature and classification of RD is the only RD-specific, high-quality standard, interoperable medical terminology and classification system that helps close the visibility gap in health and research information systems, thereby enabling the consistent recognition of people living with a rare disease and facilitating cross-border and cross-sectoral data interoperability.

Acknowledgements:

We would like to thank the Orphanet translating members for their essential contribution to the translation of the Orphanet Nomenclature of RD, as well as the European Reference Networks (ERNs) and the Filières de santé maladies rares (FSMR) for their continued involvement in nomenclature and classification revisions, and in the production of textual content.

References

1.   European Parliament: Directorate-General for Internal Policies of the Union, Kamphuis B,

De Jongh T, Bastiaanssen V. Tackling rare diseases – Challenges, opportunities and gaps

for action on rare diseases in the European Union. European Parliament; 2024. Available:

https://data.europa.eu/doi/10.2861/263904

2.   Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al.

Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet

database. Eur J Hum Genet. 2020;28: 165–173. doi:10.1038/s41431-019-0508-0

3.   European Parliament: Directorate-General for Parliamentary Research Services,

Schmiegelow K, Fehn K, Westman D, Clemente Pesudo I, Atanasovska D, et al.

Addressing challenges to European multi-country collaboration models for rare diseases.

European Parliament; 2024. Available: https://data.europa.eu/doi/10.2861/51755

4.   Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179: 885–892.

doi:10.1002/ajmg.a.61124

5.   Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet Lond Engl.

2008;372: 889–890. doi:10.1016/S0140-6736(08)61393-8

6.   Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare Disease

Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare

Disease Special Interest Group. Value Health J Int Soc Pharmacoeconomics Outcomes

Res. 2015;18: 906–914. doi:10.1016/j.jval.2015.05.008

7.   Khosla N, Valdez R. A compilation of national plans, policies and government actions for

rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7: 213–222.

doi:10.5582/irdr.2018.01085

8. Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare

diseases are there? Nat Rev Drug Discov. 2020;19: 77–78. doi:10.1038/d41573-019-

00180-y

9. Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, et al. Access and Unmet Needs of

Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content

Analysis. Value Health. 2020;23: 1580–1591. doi:10.1016/j.jval.2020.06.020

10. Wainstock D, Katz A. Advancing rare disease policy in Latin America: a call to action.

Lancet Reg Health Am. 2023;18: 100434. doi:10.1016/j.lana.2023.100434

11. Abozaid GM, Kerr K, McKnight A, Al-Omar HA. Criteria to define rare diseases and orphan

drugs: a systematic review protocol. BMJ Open. 2022;12: e062126.

doi:10.1136/bmjopen-2022-062126

12. European Parliament and Council of the European Union. Regulation (EC) No 141/2000

of the European Parliament and of the Council of 16 December 1999 on orphan

medicinal products. Publications Office of the European Union; 2000 Jan. Available:

https://eur-lex.europa.eu/eli/reg/2000/141/oj/eng

13. United States Congress. Orphan Drug Act, 21 U.S.C. § 360bb(a)(2). United States

Government Publishing Office; 2023. Available:

https://www.govinfo.gov/app/details/USCODE-2023-title21/USCODE-2023-title21-

chap9-subchapV-partB-sec360bb

14. Abozaid GM, Kerr K, Alomary H, Al-Omar HA, McKnight A. Global insight into rare disease

and orphan drug definitions: a systematic literature review. BMJ Open. 2025;15:

e086527. doi:10.1136/bmjopen-2024-086527

15. Wang CM, Whiting AH, Rath A, Anido R, Ardigò D, Baynam G, et al. Operational

description of rare diseases: a reference to improve the recognition and visibility of rare

diseases. Orphanet J Rare Dis. 2024;19: 334. doi:10.1186/s13023-024-03322-7

16. Valdez R, Ouyang L, Bolen J. Public Health and Rare Diseases: Oxymoron No More. Prev

Chronic Dis. 2016;13: E05. doi:10.5888/pcd13.150491

17. United Nations General Assembly. Addressing the challenges of persons living with a rare

disease and their families: resolution. United Nations; 2021. Available:

http://digitallibrary.un.org/record/3953832

18. Jetté N, Quan H, Hemmelgarn B, Drosler S, Maass C, Moskal L, et al. The development,

evolution, and modifications of ICD-10: challenges to the international comparability of

morbidity data. Med Care. 2010;48: 1105–1110. doi:10.1097/MLR.0b013e3181ef9d3e

19. Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of rare

diseases in health information systems: The orphanet approach to serve a wide range of

end users. Hum Mutat. 2012;33: 803–808. doi:10.1002/humu.22078

20. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health

information systems through appropriate coding. Orphanet J Rare Dis. 2015;10: 35.

doi:10.1186/s13023-015-0251-8

21. Aymé S, Rath A, Bellet B. WHO International Classification of Diseases (ICD) Revision

Process: incorporating rare diseases into the classification scheme: state of art. Orphanet

J Rare Dis. 2010;5: P1. doi:10.1186/1750-1172-5-S1-P1

22. World Health Organization. Rare diseases (frequently asked questions). In: WHO –

International Classification of Diseases [Internet]. [cited 15 June 2025]. Available:

https://www.who.int/standards/classifications/frequently-asked-questions/rare-

diseases

23. SNOMED International. INSERM and SNOMED International release SNOMED CT to

Orphanet map supporting representation and use. In: SNOMED International News

[Internet]. 2021 [cited 15 June 2025]. Available: https://www.snomed.org/news/inserm-

and-snomed-international-release-snomed-ct-to-orphanet-map-supporting-

representation-and-use

24. Commission Expert Group on Rare Diseases (CEGRD), European Commission.

Recommendation on ways to improve codification for rare diseases in health

information systems. 2014 Nov. Available:

https://health.ec.europa.eu/publications/recommendation-ways-improve-codification-

rare-diseases-health-information-systems_en

25. Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P. A methodology for

a minimum data set for rare diseases to support national centers of excellence for

healthcare and research. J Am Med Inform Assoc JAMIA. 2015;22: 76–85.

doi:10.1136/amiajnl-2014-002794

26. Council of the European Union. Council Recommendation of 8 June 2009 on an action in

the field of rare diseases. Publications Office of the European Union; 2009. Available:

https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32009H0703%2802%29

27. Kole A, Hedley V, et al. Recommendations from the Rare 2030 Foresight Study: the

future of rare diseases starts today. EURORDIS-Rare Diseases Europe (Rare2030 project);

2021 Feb. Available:

https://download2.eurordis.org/rare2030/Rare2030_recommendations.pdf

28. Orphanet, Inserm. Orphanet – Knowledge on rare diseases and orphan drugs. In:

Orphanet [Internet]. [cited 30 July 2025]. Available: http://www.orpha.net/

29. Directorate-General for Health and Food Safety, European Commission. Rare diseases.

In: European Commission – Public Health [Internet]. 2025 [cited 15 June 2025].

Available: https://health.ec.europa.eu/rare-diseases-and-european-reference-

networks/rare-diseases_en

30. European Commission – Joint Research Centre (JRC). Set of Common Data Elements for

Rare Diseases Registration. In: EU RD Platform / European Commission Science Hub

[Internet]. [cited 15 June 2025]. Available: https://eu-rd-platform.jrc.ec.europa.eu/set-

of-common-data-elements_en

31. eHAction — Joint Action supporting the eHealth Network. Common Semantic Strategy

for Health in the European Union (eHAction Deliverable D8.2.2). European Commission;

2019 May. Available: https://health.ec.europa.eu/document/download/92ac8823-19c4-

4641-bf4d-5d9bf021a600_en

32. Directorate-General for Health and Food Safety. eHN Guideline on Patient Summary

(Release 3.4). European Commission; 2024 Nov. Available:

https://health.ec.europa.eu/system/files/2023-

10/ehn_guidelines_patientsummary_en.pdf

33. X-eHealth Consortium. D5.6 – Refine PS functional specifications to account for eHN

Guidelines and rare diseases. X-eHealth: eXchanging electronic Health Records in a

commom framework; 2022. Available: https://www.x-ehealth.eu/wp-

content/uploads/2022/11/D5.6-Refine-PS-functional-specifications-to-account-for-eHN-

Guidelines-and-rare-diseases.pdf

34. Executive Board, World Health Organization. Rare diseases: a global health priority for

equity and inclusion (EB156(15)). World Health Organization; 2025 Feb. Available:

https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_(15)-en.pdf

35. Orphanet, Inserm. Procedural document: Orphanet nomenclature and classification of

rare diseases. 2023 June. Report No.: 05. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/eproc_disease_inventory_R1_

Nom_Dis_EP_05.pdf

36. Orphanet, Inserm. Procedural document: Rare disease nomenclature in English. 2017

Apr. Report No.: 1. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/eproc_Disease_naming_rules_

in_English_PR_R1_Nom_01.pdf

37. Orphanet, Inserm. Procedural document: Orphanet Rare Diseases Nomenclature

Production in National Language. 2017 Sept. Report No.: 1. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/eproc_Rare_disease_Nomencl

ature_Production__national-language.pdf

38. Angin C, Mazzucato M, Weber S, Kirch K, Abdel Khalek W, Ali H, et al. Coding

undiagnosed rare disease patients in health information systems: recommendations

from the RD-CODE project. Orphanet J Rare Dis. 2024;19: 28. doi:10.1186/s13023-024-

03030-2

39. Orphanet, Inserm. Procedural document: Linearisation rules for rare diseases. 2014 Sept.

Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/Orphanet_linearisation_rules.

pdf

40. Orphanet, Inserm. Procedural document: Collaboration with networks of expertise for

the revision of the Orphanet nomenclature and classification of rare diseases. 2024 Sept.

Report No.: 1.1. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/eproc_Collaboration_network

s_R1_Nom_Rev_Exp_EP_10.pdf

41. Orphanet, Inserm. Procedural document: Orphanet ICD-10 Coding Rules for Rare

Diseases. 2023 June. Report No.: 3. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/Orphanet_ICD10_coding_rule

s_R1_Nom_ICD_EP_07.pdf

42. World Health Organization. International statistical classification of diseases and related

health problems. 10th revision (ICD-10). 2010 edition. Geneva: World Health

Organization; Available: https://icd.who.int/browse10/2010/en

43. World Health Organization. ICD-11: International Classification of Diseases, 11th

Revision. In: ICD-11 for Mortality and Morbidity Statistics [Internet]. [cited 15 June

2025]. Available: https://icd.who.int/en

44. U.S. National Library of Medicine. Overview of SNOMED CT. In: U.S. National Library of

Medicine – Health IT [Internet]. U.S. National Library of Medicine; 2014 [cited 25 July

2025]. Available: https://www.nlm.nih.gov/healthit/snomedct/snomed_overview.html

45. SNOMED International. What is SNOMED CT. In: SNOMED International [Internet]. [cited

25 July 2025]. Available: https://www.snomed.org/what-is-snomed-ct

46. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online

Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic

disorders. Nucleic Acids Res. 2015;43: D789–D798. doi:10.1093/nar/gku1205

47. Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical

terminology. Nucleic Acids Res. 2004;32: D267–D270. doi:10.1093/nar/gkh061

48. Lipscomb CE. Medical Subject Headings (MeSH). Bull Med Libr Assoc. 2000;88: 265–266.

49. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA).

Drug Saf. 1999;20: 109–117. doi:10.2165/00002018-199920020-00002

50. National Center for Advancing Translational Sciences (NCATS), National Institutes of

Health. Genetic and Rare Diseases Information Center (GARD). In: Genetic and Rare

Diseases Information Center [Internet]. [cited 15 June 2025]. Available:

https://rarediseases.info.nih.gov/

51. Vasilevsky NA, Matentzoglu NA, Toro S, Flack JE, Hegde H, Unni DR, et al. Mondo:

Unifying diseases for the world, by the world. medRxiv; 2022. p. 2022.04.13.22273750.

doi:10.1101/2022.04.13.22273750

52. Orphanet, Inserm. Orphadata Science – Orphanet datasets. In: Science Orphadata

[Internet]. 2025 [cited 30 July 2025]. Available: https://sciences.orphadata.com/

53. Orphanet, Inserm. Orphadata aggregated. In: GitHub [Internet]. 9 July 2025 [cited 25 July

2025]. Available: https://github.com/Orphanet/Orphadata_aggregated

54. Orphanet, Inserm. Orphanet Nomenclature Pack for Coding. In: ORPHAcodes [Internet].

2025 [cited 25 July 2025]. Available: https://www.orphacode.org/pack-nomenclature/

55. Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical

and social issue. The Lancet. 2008;371: 2039–2041. doi:10.1016/S0140-6736(08)60872-7

56. Direction générale de l'offre de soins, France numérique santé (e-Santé) – Ministry of

Health, France. Référentiels d'intéropérabilité sémantique : mise en euvre de

terminologies de référence pour le secteur santé-social en France. Ministère des

Solidarités et de la Santé, France; 2015. Available:

https://esante.gouv.fr/sites/default/files/media_entity/documents/20150504_etude_te

rminos_phase2_diagnostic.pdf

57. Ministerio de Salud de la Nación, Argentina. Listado de enfermedades poco frecuentes

en Argentina. In: Argentina.gob.ar – Salud [Internet]. [cited 15 June 2025]. Available:

https://www.argentina.gob.ar/salud/pocofrecuentes/listado

58. RARE-X Data Platform (RARE-X), Lamoreaux K, et al. The Power of Being Counted: A

more accurate count of rare diseases and steps to getting counted. RARE-X Data

Platform; 2022 May. Available: https://rare-x.org/wp-content/uploads/2022/05/be-

counted-052722-WEB.pdf

59. Smith CIE, Bergman P, Hagey DW. Estimating the number of diseases – the concept of

rare, ultra-rare, and hyper-rare. iScience. 2022;25: 104698.

doi:10.1016/j.isci.2022.104698

60. European Commission (Directorate-General for Health and Food Safety). European

Reference Networks. In: European Commission – Public Health [Internet]. [cited 25 July

2025]. Available: https://health.ec.europa.eu/rare-diseases-and-european-reference-

networks/european-reference-networks_en

61. Orphanet, Inserm. Procedural document: Creation and update of disease summary texts

for the Orphanet encyclopaedia for professionals. 2021 June. Report No.: 2. Available:

https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/Orphanet_DiseaseSummaryTe

xt_R1_Prod_sum_EP_02.pdf

62. Mazzucato M, Pozza LVD, Facchin P, Angin C, Agius F, Cavero-Carbonell C, et al.

ORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross

country comparability. Orphanet J Rare Dis. 2023;18: 267. doi:10.1186/s13023-023-

02864-6

63. Mazzucato M, Visonà Dalla Pozza L, Minichiello C, Toto E, Vianello A, Facchin P.

Estimating mortality in rare diseases using a population-based registry, 2002 through

2019. Orphanet J Rare Dis. 2023;18: 362. doi:10.1186/s13023-023-02944-7

64. Pichon T, Messiaen C, Soussand L, Angin C, Sandrin A, Elarouci N, et al. Overview of

patients' cohorts in the French National rare disease registry. Orphanet J Rare Dis.

2023;18: 176. doi:10.1186/s13023-023-02725-2

65. Gunne E, McGarvey C, Hamilton K, Treacy E, Lambert DM, Lynch SA. A retrospective

review of the contribution of rare diseases to paediatric mortality in Ireland. Orphanet J

Rare Dis. 2020;15: 311. doi:10.1186/s13023-020-01574-7

66. Rico J, Echevarría-González de Garibay LJ, García-López M, Guardiola-Vilarroig S,

Maceda-Roldán LA, Zurriaga Ó, et al. The interoperability between the Spanish version of

the International Classification of Diseases and ORPHAcodes: towards better

identification of rare diseases. Orphanet J Rare Dis. 2021;16: 121. doi:10.1186/s13023-

021-01763-y

67. Walker CE, Mahede T, Davis G, Miller LJ, Girschik J, Brameld K, et al. The collective

impact of rare diseases in Western Australia: an estimate using a population-based

cohort. Genet Med. 2017;19: 546–552. doi:10.1038/gim.2016.143

68. Scanlon P, Ridler G, Say G, Kellett M, Charlesworth J, Neil A, et al. Measuring the impact

of rare diseases in Tasmania, Australia. Orphanet J Rare Dis. 2024;19: 399.

doi:10.1186/s13023-024-03343-2

69. International Rare Diseases Research Consortium (IRDiRC). IRDiRC Vision & Goals. In:

IRDiRC (irdirc.org) [Internet]. [cited 15 June 2025]. Available: https://irdirc.org/about-

us/vision-goals/

70. Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, et al. International

Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am J Hum Genet.

2017;100: 695–705. doi:10.1016/j.ajhg.2017.04.003

71. Lochmüller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, et al. 'IRDiRC

Recognized Resources': a new mechanism to support scientists to conduct efficient,

high-quality research for rare diseases. Eur J Hum Genet. 2017;25: 162–165.

doi:10.1038/ejhg.2016.137

72. Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare

diseases in Hong Kong – adopting ORPHAcodes in ICD-10 based healthcare

administrative datasets. Orphanet J Rare Dis. 2018;13: 147. doi:10.1186/s13023-018-

0892-5

73. Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now?

The impact of health-care utilization by rare disease patients in the United States. Genet

Med. 2021;23: 2194–2201. doi:10.1038/s41436-021-01241-7

74. Work Package 5, RD-ACTION Joint Action. Recommendation for routine maintenance of

codification resources for rare diseases (RD-ACTION Deliverable 5.5). European

Commission (Health Programme) / RD-ACTION; 2018 July. Available: https://www.rd-

action.eu/wp-content/uploads/2018/09/677024_DEL5.5_Recommendation-routine-

maintenance-codification.pdf

Supporting information captions

S1 File. Distribution of Orphanet clinical entities by classification level and typology. This file is the output of Notebook 1_number_of_Orphanet_clinical_entities.

S2 File. Production of the Orphanet RD terminology in English and translation languages. This file is the output of Notebook 2_production_of_the_Orphanet_RD_terminology_in_english_and_other_languages.

S3 File. Distribution of disorders in Orphanet classifications according to their preferential parent and multiclassified disorders. This file combines the outputs of Notebook 5_distribution_of_Orphanet_RD_in_Orphanet_classifications and Notebook 6_distribution_of_Orphanet_RD_by_preferential_parent.

ORPHAcode	Preferred term	Synonyms	Classification level
ORPHA:2134	Atypical hemolytic uremic syndrome	Atypical HUS aHUS	Disorder
Definition	A rare, genetic thrombotic microangiopathy due to dysregulation of the alternative complement pathway and characterized by the triad of hemolytic anemia, thrombocytopenia, and acute renal dysfunction.		

Figure 1

Figure 2

Figure 3

Figure 4